CA2387145A1 - Compositions de sels d'argent encapsulees dans un liposome - Google Patents

Compositions de sels d'argent encapsulees dans un liposome Download PDF

Info

Publication number
CA2387145A1
CA2387145A1 CA002387145A CA2387145A CA2387145A1 CA 2387145 A1 CA2387145 A1 CA 2387145A1 CA 002387145 A CA002387145 A CA 002387145A CA 2387145 A CA2387145 A CA 2387145A CA 2387145 A1 CA2387145 A1 CA 2387145A1
Authority
CA
Canada
Prior art keywords
silver
composition
group
liposomes
encapsulated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002387145A
Other languages
English (en)
Inventor
Valerio Ditizio
Lori Burrows
Frank Dicosmo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Covalon Technologies Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2387145A1 publication Critical patent/CA2387145A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/38—Silver; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Anesthesiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne des compositions encapsulées de sels d'argent destinées au traitement d'infections de surface et de plaies profondes et d'autres régions sujettes aux infections bactériennes et fongiques. Les compositions renferment un lactate d'argent encapsulé dans un liposome ou d'autres sels d'argent adéquats dans un excipient pharmaceutiquement acceptable.
CA002387145A 1999-10-14 2000-10-13 Compositions de sels d'argent encapsulees dans un liposome Abandoned CA2387145A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15942799P 1999-10-14 1999-10-14
US60/159,427 1999-10-14
PCT/CA2000/001199 WO2001026627A1 (fr) 1999-10-14 2000-10-13 Compositions de sels d'argent encapsulees dans un liposome

Publications (1)

Publication Number Publication Date
CA2387145A1 true CA2387145A1 (fr) 2001-04-19

Family

ID=22572579

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002387145A Abandoned CA2387145A1 (fr) 1999-10-14 2000-10-13 Compositions de sels d'argent encapsulees dans un liposome

Country Status (5)

Country Link
EP (1) EP1220657A1 (fr)
JP (1) JP2003511404A (fr)
AU (1) AU7767200A (fr)
CA (1) CA2387145A1 (fr)
WO (1) WO2001026627A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60216305T2 (de) * 2001-10-03 2007-07-05 Celator Pharmaceuticals, Inc. Zusammensetzungen und Verfahren zur Abgabe von Arzneimittelkombinationen
US7850990B2 (en) 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
CA2383259A1 (fr) 2002-04-23 2003-10-23 Celator Technologies Inc. Composes synergiques
FR2853548B1 (fr) * 2003-04-11 2008-09-05 Mayoly Spindler Lab Nouvelles utilisations du proteinate d'argent dans la prevention du syndrome respiratoire aigu severe(sras)
ES2313031T3 (es) * 2003-06-20 2009-03-01 JOHNSON & JOHNSON MEDICAL LTD. Antimicrobianos que comprenden plata.
JP2005104924A (ja) * 2003-09-30 2005-04-21 Kobayashi Pharmaceut Co Ltd 外用医薬組成物
US8865227B2 (en) 2007-12-20 2014-10-21 Smith & Nephew (Overseas) Limited Metal carbonate particles and methods of making thereof
EP2361502A1 (fr) * 2010-02-05 2011-08-31 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Compositions antimicrobiennes actives, revêtements et procédés de contrôle des bactéries pathogènes
GB201200490D0 (en) 2012-01-12 2012-02-22 Univ Bath Wound dressing
WO2022036264A1 (fr) * 2020-08-13 2022-02-17 Tom Johnson Compositions désinfectantes et leurs procédés de fabrication et d'utilisation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB929406A (en) * 1958-12-22 1963-06-19 Upjohn Co A process for the production of encapsulated material
US4391799A (en) * 1980-02-15 1983-07-05 The United States Of America As Represented By The Secretary Of The Army Protective gel composition for treating white phosphorus burn wounds
US4563184A (en) * 1983-10-17 1986-01-07 Bernard Korol Synthetic resin wound dressing and method of treatment using same
EP0355009A1 (fr) * 1988-08-18 1990-02-21 Konrad Minninger Produit pharmaceutique contenant du sulfadiazinat d'argent pour thérapie externe, locale
DK0455706T3 (da) * 1989-01-27 1997-10-13 Giltech Ltd Medicinsk substans til topisk anvendelse.
FR2689418B1 (fr) * 1992-04-03 1994-07-01 Centre Nat Rech Scient Procede de preparation de micro-capsules ou de liposomes de tailles controlees par application d'un cisaillement constant sur une phase lamellaire.

Also Published As

Publication number Publication date
AU7767200A (en) 2001-04-23
WO2001026627A1 (fr) 2001-04-19
JP2003511404A (ja) 2003-03-25
EP1220657A1 (fr) 2002-07-10

Similar Documents

Publication Publication Date Title
Beaulac et al. In-vitro bactericidal efficacy of sub-MIC concentrations of liposome-encapsulated antibiotic against gram-negative and gram-positive bacteria.
US5874104A (en) Treatment of systemic fungal infections with phospholipid particles encapsulating polyene antibiotics
JP2703594B2 (ja) リポソーム含有ニスタチン
US6770290B1 (en) Amphotericin B liposome preparation
CA1237671A (fr) Augmentation de l'activite pharmaceutique
EP2079443B1 (fr) Préparations inhalées, à double action permettant d'obtenir un profil de libération immédiate et prolongée
Tremblay et al. Efficacy of liposome-intercalated amphotericin B in the treatment of systemic candidiasis in mice
US5662929A (en) Therapeutic liposomal formulation
AU2014340568B2 (en) Inhaled surfactant-modified liposomal formulations providing both an immediate and sustained release profile
PT1909759E (pt) Libertação controlada de agentes anti-infeciosos
US6613352B2 (en) Low-rigidity liposomal formulation
US4978654A (en) Composition and method for treatment of disseminated fungal infections in mammals
US5032404A (en) Lipsome-incorporation of polyenes
CA2387145A1 (fr) Compositions de sels d'argent encapsulees dans un liposome
WO2001032218A1 (fr) Compositions et procedes d'apport avec liberation retard et puissance accrue de produits pharmaceutiques, par appariement d'ions hydrophobes
JP5920875B2 (ja) 真菌感染症を治療するための新規な製剤
US20120207821A1 (en) Liposomal formulation and use thereof
US5043107A (en) Preparation small unilamellar vesicles including polyene antifungal antibiotics
CN1939340A (zh) 脂质体制剂
US20040175417A1 (en) Amphotericin B liposome preparation
Beaulac et al. In vitro bactericidal evaluation of a low phase transition temperature liposomal tobramycin formulation as a dry powder preparation against Gram negative and Gram positive bacteria
Karki International Journal of Biomedical and Advance Research 69

Legal Events

Date Code Title Description
FZDE Dead